This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Tetrahydropalmatine
Accession Number
DB12093
Type
Small Molecule
Groups
Investigational
Description

Tetrahydropalmatine is under investigation in clinical trial NCT02118610 (Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity).

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Tetrahydropalmatine HydrochlorideRH72T8K75E4880-82-4MGSZZQQRTPWMEI-LMOVPXPDSA-N
Categories
UNII
3X69CO5I79
CAS number
483-14-7
Weight
Average: 355.434
Monoisotopic: 355.178358289
Chemical Formula
C21H25NO4
InChI Key
AEQDJSLRWYMAQI-KRWDZBQOSA-N
InChI
InChI=1S/C21H25NO4/c1-23-18-6-5-13-9-17-15-11-20(25-3)19(24-2)10-14(15)7-8-22(17)12-16(13)21(18)26-4/h5-6,10-11,17H,7-9,12H2,1-4H3/t17-/m0/s1
IUPAC Name
(12bS)-3,4,10,11-tetramethoxy-7,8,12b,13-tetrahydro-5H-6-azatetraphene
SMILES
COC1=CC=C2C[[email protected]@H]3N(CCC4=CC(OC)=C(OC)C=C34)CC2=C1OC

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UD(1A) dopamine receptor
antagonist
Human
UD(2) dopamine receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Tetrahydropalmatine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Tetrahydropalmatine.Vet Approved
2,5-Dimethoxy-4-ethylamphetamineTetrahydropalmatine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineTetrahydropalmatine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineTetrahydropalmatine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tetrahydropalmatine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Tetrahydropalmatine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Tetrahydropalmatine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Tetrahydropalmatine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Tetrahydropalmatine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tetrahydropalmatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tetrahydropalmatine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tetrahydropalmatine.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Tetrahydropalmatine.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Tetrahydropalmatine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tetrahydropalmatine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tetrahydropalmatine.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Withdrawn
AmbrisentanTetrahydropalmatine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineTetrahydropalmatine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Amitriptyline.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Tetrahydropalmatine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tetrahydropalmatine.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Tetrahydropalmatine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Tetrahydropalmatine.Experimental
AmphetamineTetrahydropalmatine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tetrahydropalmatine.Approved, Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Tetrahydropalmatine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetrahydropalmatine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Tetrahydropalmatine.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Tetrahydropalmatine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Tetrahydropalmatine.Approved
AtenololAtenolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Atosiban.Approved
Atracurium besylateTetrahydropalmatine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Tetrahydropalmatine.Vet Approved
AzelastineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Baclofen.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Tetrahydropalmatine.Experimental
BarbexacloneThe metabolism of Tetrahydropalmatine can be increased when combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Tetrahydropalmatine.Illicit
BenazeprilBenazepril may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Tetrahydropalmatine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tetrahydropalmatine.Approved
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Tetrahydropalmatine.Approved
BenzphetamineTetrahydropalmatine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tetrahydropalmatine.Approved
BepridilBepridil may increase the hypotensive activities of Tetrahydropalmatine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
BethanidineBethanidine may increase the hypotensive activities of Tetrahydropalmatine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Tetrahydropalmatine.Experimental
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Tetrahydropalmatine.Approved
BimatoprostBimatoprost may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
BosentanBosentan may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
BQ-123BQ-123 may increase the hypotensive activities of Tetrahydropalmatine.Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when 1,6,7,8,9,11A,12,13,14,14A-DECAHYDRO-1,13-DIHYDROXY-6-METHYL-4H-CYCLOPENT[F]OXACYCLOTRIDECIN-4-ONE is combined with Tetrahydropalmatine.Experimental
BretyliumBretylium may increase the hypotensive activities of Tetrahydropalmatine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Tetrahydropalmatine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Tetrahydropalmatine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tetrahydropalmatine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tetrahydropalmatine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Tetrahydropalmatine.Approved, Withdrawn
BucindololBucindolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
BunazosinBunazosin may increase the hypotensive activities of Tetrahydropalmatine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tetrahydropalmatine.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
BuprenorphineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tetrahydropalmatine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tetrahydropalmatine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Tetrahydropalmatine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Tetrahydropalmatine.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Tetrahydropalmatine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Tetrahydropalmatine.Approved, Illicit
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Tetrahydropalmatine.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tetrahydropalmatine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tetrahydropalmatine.Approved
CadralazineCadralazine may increase the hypotensive activities of Tetrahydropalmatine.Experimental
CafedrineTetrahydropalmatine may increase the hypotensive activities of Cafedrine.Investigational
CalciumThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Carbonate.Approved
Calcium CitrateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Phosphate.Approved
CandesartanCandesartan may increase the hypotensive activities of Tetrahydropalmatine.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Tetrahydropalmatine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Tetrahydropalmatine.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Tetrahydropalmatine.Investigational
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Tetrahydropalmatine.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Tetrahydropalmatine.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tetrahydropalmatine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Carbinoxamine.Approved
CarbomycinThe metabolism of Tetrahydropalmatine can be decreased when combined with Carbomycin.Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Tetrahydropalmatine.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Carisoprodol.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
CaseinThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Tetrahydropalmatine.Approved
CeliprololCeliprolol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
CerivastatinThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Tetrahydropalmatine.Approved
CetirizineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tetrahydropalmatine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tetrahydropalmatine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Tetrahydropalmatine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tetrahydropalmatine.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Tetrahydropalmatine.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Tetrahydropalmatine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Chlorphenamine.Approved
ChlorphentermineTetrahydropalmatine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Tetrahydropalmatine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tetrahydropalmatine.Approved, Withdrawn
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Tetrahydropalmatine.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Chlorzoxazone.Approved
CicletanineTetrahydropalmatine may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Tetrahydropalmatine.Approved, Investigational
CilazaprilCilazapril may increase the hypotensive activities of Tetrahydropalmatine.Approved
CimetidineThe serum concentration of Tetrahydropalmatine can be increased when it is combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tetrahydropalmatine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Tetrahydropalmatine.Approved
ClarithromycinThe metabolism of Tetrahydropalmatine can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Tetrahydropalmatine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tetrahydropalmatine.Approved, Nutraceutical
CloranololTetrahydropalmatine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tetrahydropalmatine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Clothiapine.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Tetrahydropalmatine.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Tetrahydropalmatine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tetrahydropalmatine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tetrahydropalmatine.Approved, Illicit
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Tetrahydropalmatine.Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Tetrahydropalmatine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrahydropalmatine.Approved
CyclopenthiazideTetrahydropalmatine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Tetrahydropalmatine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Tetrahydropalmatine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Tetrahydropalmatine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Tetrahydropalmatine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Tetrahydropalmatine.Approved
DelaprilTetrahydropalmatine may increase the hypotensive activities of Delapril.Experimental
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Tetrahydropalmatine.Investigational
DeserpidineTetrahydropalmatine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tetrahydropalmatine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Tetrahydropalmatine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Tetrahydropalmatine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tetrahydropalmatine.Approved, Vet Approved
DextroamphetamineTetrahydropalmatine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Tetrahydropalmatine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tetrahydropalmatine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tetrahydropalmatine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Tetrahydropalmatine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tetrahydropalmatine.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Tetrahydropalmatine.Approved
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Tetrahydropalmatine.Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Diethyl ether.Experimental
diethylnorsperminediethylnorspermine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
DiethylpropionTetrahydropalmatine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Difenoxin.Approved, Illicit
DihydralazineDihydralazine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tetrahydropalmatine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tetrahydropalmatine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tetrahydropalmatine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tetrahydropalmatine.Experimental, Illicit
DiltiazemDiltiazem may increase the hypotensive activities of Tetrahydropalmatine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Tetrahydropalmatine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tetrahydropalmatine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Tetrahydropalmatine.Vet Approved
DorzolamideDorzolamide may increase the hypotensive activities of Tetrahydropalmatine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Tetrahydropalmatine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Tetrahydropalmatine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Tetrahydropalmatine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Tetrahydropalmatine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tetrahydropalmatine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Tetrahydropalmatine.Experimental, Illicit
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Tetrahydropalmatine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Tetrahydropalmatine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Tetrahydropalmatine.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Tetrahydropalmatine.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Tetrahydropalmatine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Eltanolone.Investigational
EnalaprilEnalapril may increase the hypotensive activities of Tetrahydropalmatine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Tetrahydropalmatine.Approved
EndralazineEndralazine may increase the hypotensive activities of Tetrahydropalmatine.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tetrahydropalmatine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Entacapone.Approved, Investigational
EpanololTetrahydropalmatine may increase the hypotensive activities of Epanolol.Experimental
EpoprostenolEpoprostenol may increase the hypotensive activities of Tetrahydropalmatine.Approved
EprosartanEprosartan may increase the hypotensive activities of Tetrahydropalmatine.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tetrahydropalmatine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tetrahydropalmatine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Tetrahydropalmatine.Approved
ErythromycinThe metabolism of Tetrahydropalmatine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Tetrahydropalmatine.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tetrahydropalmatine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tetrahydropalmatine.Approved
EthanolTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tetrahydropalmatine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tetrahydropalmatine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tetrahydropalmatine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tetrahydropalmatine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Tetrahydropalmatine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Tetrahydropalmatine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Tetrahydropalmatine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrahydropalmatine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tetrahydropalmatine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Felbamate.Approved
FelodipineFelodipine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Tetrahydropalmatine.Approved, Illicit, Withdrawn
FenoldopamFenoldopam may increase the hypotensive activities of Tetrahydropalmatine.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tetrahydropalmatine.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Tetrahydropalmatine.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Tetrahydropalmatine.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Fluanisone.Experimental
FluconazoleThe serum concentration of Tetrahydropalmatine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Tetrahydropalmatine.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tetrahydropalmatine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tetrahydropalmatine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Tetrahydropalmatine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Tetrahydropalmatine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tetrahydropalmatine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tetrahydropalmatine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Tetrahydropalmatine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Fluticasone propionate.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Tetrahydropalmatine.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tetrahydropalmatine.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Tetrahydropalmatine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Tetrahydropalmatine.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tetrahydropalmatine.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Tetrahydropalmatine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Tetrahydropalmatine.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tetrahydropalmatine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tetrahydropalmatine.Approved, Illicit
GepefrineTetrahydropalmatine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Tetrahydropalmatine.Approved, Illicit
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Tetrahydropalmatine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Tetrahydropalmatine.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Tetrahydropalmatine.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Tetrahydropalmatine.Approved
GuanazodineTetrahydropalmatine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Tetrahydropalmatine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Guanfacine.Approved, Investigational
GuanoclorTetrahydropalmatine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzTetrahydropalmatine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanTetrahydropalmatine may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Tetrahydropalmatine.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Tetrahydropalmatine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tetrahydropalmatine.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Tetrahydropalmatine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tetrahydropalmatine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Tetrahydropalmatine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Tetrahydropalmatine.Approved, Illicit
HexamethoniumHexamethonium may increase the hypotensive activities of Tetrahydropalmatine.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Tetrahydropalmatine.Approved
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tetrahydropalmatine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Tetrahydropalmatine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Tetrahydropalmatine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Tetrahydropalmatine.Approved, Vet Approved
HydrocodoneTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Tetrahydropalmatine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tetrahydropalmatine.Approved, Illicit
HydroxyamphetamineTetrahydropalmatine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
ImidaprilImidapril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Tetrahydropalmatine.Approved
IndenololIndenolol may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Indiplon.Investigational
IndoraminIndoramin may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
Iofetamine I-123Tetrahydropalmatine may decrease the stimulatory activities of Iofetamine I-123.Approved
IproclozideIproclozide may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Tetrahydropalmatine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Tetrahydropalmatine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tetrahydropalmatine.Approved, Vet Approved
IsradipineIsradipine may increase the hypotensive activities of Tetrahydropalmatine.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Tetrahydropalmatine.Approved, Investigational
JosamycinThe metabolism of Tetrahydropalmatine can be decreased when combined with Josamycin.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetrahydropalmatine.Approved, Vet Approved
KetanserinKetanserin may increase the hypotensive activities of Tetrahydropalmatine.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tetrahydropalmatine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tetrahydropalmatine.Approved
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Tetrahydropalmatine.Approved, Investigational
KitasamycinThe metabolism of Tetrahydropalmatine can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Tetrahydropalmatine.Approved
LacidipineLacidipine may increase the hypotensive activities of Tetrahydropalmatine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Lamotrigine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tetrahydropalmatine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tetrahydropalmatine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Tetrahydropalmatine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tetrahydropalmatine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tetrahydropalmatine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Tetrahydropalmatine.Approved, Investigational
LinsidomineTetrahydropalmatine may increase the hypotensive activities of Linsidomine.Experimental
LisdexamfetamineTetrahydropalmatine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilLisinopril may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Tetrahydropalmatine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Tetrahydropalmatine.Illicit
LofexidineLofexidine may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tetrahydropalmatine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Tetrahydropalmatine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Lormetazepam.Approved
LosartanLosartan may increase the hypotensive activities of Tetrahydropalmatine.Approved
LovastatinThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tetrahydropalmatine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Tetrahydropalmatine.Approved
MacitentanTetrahydropalmatine may increase the hypotensive activities of Macitentan.Approved
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Magnesium salicylate.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved, Vet Approved
ManidipineManidipine may increase the hypotensive activities of Tetrahydropalmatine.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Maprotiline.Approved
MebanazineMebanazine may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Mebicar.Experimental
MecamylamineMecamylamine may increase the hypotensive activities of Tetrahydropalmatine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Tetrahydropalmatine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Tetrahydropalmatine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Tetrahydropalmatine.Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Tetrahydropalmatine.Experimental
MephedroneTetrahydropalmatine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineTetrahydropalmatine may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetrahydropalmatine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrahydropalmatine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Meptazinol.Experimental
MequitazineTetrahydropalmatine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Tetrahydropalmatine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Tetrahydropalmatine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tetrahydropalmatine.Approved, Illicit
MethamphetamineTetrahydropalmatine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tetrahydropalmatine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tetrahydropalmatine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tetrahydropalmatine.Approved
MethoserpidineTetrahydropalmatine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tetrahydropalmatine.Approved, Vet Approved
MethoxyphenamineTetrahydropalmatine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Methsuximide.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Tetrahydropalmatine.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Tetrahydropalmatine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Tetrahydropalmatine.Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tetrahydropalmatine.Approved
MetipranololMetipranolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Tetrahydropalmatine.Approved, Investigational
MetolazoneMetolazone may increase the hypotensive activities of Tetrahydropalmatine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
MetyrosineTetrahydropalmatine may increase the sedative activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Tetrahydropalmatine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Tetrahydropalmatine.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetrahydropalmatine.Approved, Illicit
MidomafetamineTetrahydropalmatine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Tetrahydropalmatine.Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Tetrahydropalmatine.Approved
MinaprineMinaprine may increase the hypotensive activities of Tetrahydropalmatine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved, Investigational
MinoxidilMinoxidil may increase the hypotensive activities of Tetrahydropalmatine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Tetrahydropalmatine.Investigational
MirtazapineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumTetrahydropalmatine may increase the neuromuscular blocking activities of Mivacurium.Approved
MMDATetrahydropalmatine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the hypotensive activities of Tetrahydropalmatine.Approved
MoexiprilMoexipril may increase the hypotensive activities of Tetrahydropalmatine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Tetrahydropalmatine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Tetrahydropalmatine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Tetrahydropalmatine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tetrahydropalmatine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Tetrahydropalmatine.Approved
MuzolimineTetrahydropalmatine may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Tetrahydropalmatine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved, Investigational
NadololNadolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
NafcillinThe metabolism of Tetrahydropalmatine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Tetrahydropalmatine.Approved
NaftopidilNaftopidil may increase the hypotensive activities of Tetrahydropalmatine.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Tetrahydropalmatine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Tetrahydropalmatine.Approved, Investigational
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Tetrahydropalmatine.Approved
NebivololNebivolol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Tetrahydropalmatine.Approved, Withdrawn
NialamideNialamide may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Tetrahydropalmatine.Approved
NicorandilNicorandil may increase the hypotensive activities of Tetrahydropalmatine.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Tetrahydropalmatine.Experimental
NiguldipineNiguldipine may increase the hypotensive activities of Tetrahydropalmatine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Tetrahydropalmatine.Investigational
NilvadipineNilvadipine may increase the hypotensive activities of Tetrahydropalmatine.Approved
NimodipineNimodipine may increase the hypotensive activities of Tetrahydropalmatine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Tetrahydropalmatine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tetrahydropalmatine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Tetrahydropalmatine.Approved
NitroprussideTetrahydropalmatine may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tetrahydropalmatine.Approved, Vet Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Tetrahydropalmatine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Tetrahydropalmatine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Nortriptyline.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Tetrahydropalmatine.Approved, Vet Approved
ObinutuzumabTetrahydropalmatine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tetrahydropalmatine.Approved, Investigational
OleandomycinThe metabolism of Tetrahydropalmatine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanOlmesartan may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Olopatadine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Tetrahydropalmatine.Investigational
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Tetrahydropalmatine.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Tetrahydropalmatine.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Tetrahydropalmatine.Approved, Illicit
OrphenadrineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Tetrahydropalmatine.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tetrahydropalmatine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Oxethazaine.Investigational
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Tetrahydropalmatine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tetrahydropalmatine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tetrahydropalmatine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tetrahydropalmatine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tetrahydropalmatine.Approved, Investigational, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Tetrahydropalmatine.Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Tetrahydropalmatine.Approved
ParaldehydeTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylinePargyline may increase the hypotensive activities of Tetrahydropalmatine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Tetrahydropalmatine.Approved, Investigational
PenbutololPenbutolol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Penfluridol.Experimental
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Tetrahydropalmatine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Tetrahydropalmatine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tetrahydropalmatine.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Tetrahydropalmatine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved
PerazineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Perazine.Investigational
PerindoprilPerindopril may increase the hypotensive activities of Tetrahydropalmatine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Tetrahydropalmatine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Tetrahydropalmatine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tetrahydropalmatine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Tetrahydropalmatine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Phenibut.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tetrahydropalmatine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Tetrahydropalmatine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Tetrahydropalmatine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
PhentermineTetrahydropalmatine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolaminePhentolamine may increase the hypotensive activities of Tetrahydropalmatine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Tetrahydropalmatine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Tetrahydropalmatine.Approved
PinacidilPinacidil may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
PindololPindolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tetrahydropalmatine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Piritramide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Tetrahydropalmatine.Approved
PitavastatinThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Pitavastatin.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Pizotifen.Approved
PolythiazidePolythiazide may increase the hypotensive activities of Tetrahydropalmatine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Pomalidomide.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Tetrahydropalmatine.Approved, Investigational, Vet Approved
PramipexoleTetrahydropalmatine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tetrahydropalmatine.Approved
PravastatinThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Pravastatin.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Tetrahydropalmatine.Approved, Illicit
PrazosinPrazosin may increase the hypotensive activities of Tetrahydropalmatine.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tetrahydropalmatine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tetrahydropalmatine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tetrahydropalmatine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Tetrahydropalmatine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetrahydropalmatine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Tetrahydropalmatine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tetrahydropalmatine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tetrahydropalmatine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Tetrahydropalmatine.Approved
PropranololPropranolol may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Tetrahydropalmatine.Investigational
PseudoephedrineTetrahydropalmatine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Tetrahydropalmatine.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tetrahydropalmatine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Tetrahydropalmatine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Tetrahydropalmatine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Tetrahydropalmatine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Raclopride.Investigational
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Tetrahydropalmatine.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ramelteon.Approved, Investigational
RamiprilRamipril may increase the hypotensive activities of Tetrahydropalmatine.Approved
RapacuroniumTetrahydropalmatine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Tetrahydropalmatine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetrahydropalmatine.Approved
RemikirenRemikiren may increase the hypotensive activities of Tetrahydropalmatine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Tetrahydropalmatine.Approved, Withdrawn
RescinnamineTetrahydropalmatine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Tetrahydropalmatine.Approved
RifabutinThe serum concentration of Tetrahydropalmatine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Tetrahydropalmatine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Tetrahydropalmatine can be decreased when it is combined with Rifapentine.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
RiociguatTetrahydropalmatine may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Tetrahydropalmatine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ritanserin.Investigational
RitobegronTetrahydropalmatine may decrease the stimulatory activities of Ritobegron.Investigational
RituximabTetrahydropalmatine may increase the hypotensive activities of Rituximab.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Tetrahydropalmatine.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Tetrahydropalmatine.Vet Approved
RopiniroleTetrahydropalmatine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tetrahydropalmatine.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Rosuvastatin.Approved
RotigotineTetrahydropalmatine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tetrahydropalmatine.Approved
SafrazineSafrazine may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Tetrahydropalmatine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tetrahydropalmatine.Approved, Vet Approved
SaprisartanSaprisartan may increase the hypotensive activities of Tetrahydropalmatine.Experimental
ScopolamineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetrahydropalmatine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Tetrahydropalmatine.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Sepranolone.Investigational
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Tetrahydropalmatine.Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Tetrahydropalmatine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Tetrahydropalmatine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tetrahydropalmatine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Tetrahydropalmatine.Approved, Investigational
SilodosinSilodosin may increase the hypotensive activities of Tetrahydropalmatine.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Tetrahydropalmatine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Tetrahydropalmatine.Approved, Investigational
SitaxentanTetrahydropalmatine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved
SolithromycinThe metabolism of Tetrahydropalmatine can be decreased when combined with Solithromycin.Investigational
SpiraprilSpirapril may increase the hypotensive activities of Tetrahydropalmatine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrahydropalmatine.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Tetrahydropalmatine.Approved
SulpirideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Tetrahydropalmatine.Approved, Investigational
SuvorexantTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TadalafilTadalafil may increase the antihypertensive activities of Tetrahydropalmatine.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Tasimelteon.Approved
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Tetrahydropalmatine.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Tetrahydropalmatine.Approved
TelithromycinThe metabolism of Tetrahydropalmatine can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tetrahydropalmatine.Approved
TemocaprilTemocapril may increase the hypotensive activities of Tetrahydropalmatine.Experimental, Investigational
TerazosinTerazosin may increase the hypotensive activities of Tetrahydropalmatine.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Tetrahydropalmatine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Tetrahydropalmatine.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tetrahydropalmatine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tetrahydropalmatine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tetrahydropalmatine.Investigational
ThalidomideTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineTetrahydropalmatine may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetrahydropalmatine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tetrahydropalmatine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Tetrahydropalmatine.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Tetrahydropalmatine.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Tetrahydropalmatine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Tiapride.Approved, Investigational
TiboloneTibolone may increase the hypotensive activities of Tetrahydropalmatine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Tetrahydropalmatine.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Tetrahydropalmatine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Tilidine.Experimental
TimololTimolol may increase the hypotensive activities of Tetrahydropalmatine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Tetrahydropalmatine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Tizanidine.Approved
TolazolineTolazoline may increase the hypotensive activities of Tetrahydropalmatine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Tolcapone.Approved, Withdrawn
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Tetrahydropalmatine.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Tetrahydropalmatine.Approved, Vet Approved
TolonidineTetrahydropalmatine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Tetrahydropalmatine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Topiramate.Approved
TorasemideTorasemide may increase the hypotensive activities of Tetrahydropalmatine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetrahydropalmatine.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Tetrahydropalmatine.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Tetrahydropalmatine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetrahydropalmatine.Approved
TravoprostTravoprost may increase the hypotensive activities of Tetrahydropalmatine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Tetrahydropalmatine.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tetrahydropalmatine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Tetrahydropalmatine.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Tetrahydropalmatine.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tetrahydropalmatine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Tetrahydropalmatine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Tetrahydropalmatine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Tetrahydropalmatine.Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Tetrahydropalmatine.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Triprolidine.Approved
TylosinThe metabolism of Tetrahydropalmatine can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ubidecarenone.Experimental
UdenafilUdenafil may increase the antihypertensive activities of Tetrahydropalmatine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Tetrahydropalmatine.Approved
UrapidilUrapidil may increase the hypotensive activities of Tetrahydropalmatine.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tetrahydropalmatine.Approved, Investigational
ValsartanValsartan may increase the hypotensive activities of Tetrahydropalmatine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Tetrahydropalmatine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Tetrahydropalmatine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Tetrahydropalmatine.Approved
VincamineTetrahydropalmatine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineTetrahydropalmatine may increase the hypotensive activities of Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Vinyl ether.Experimental
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Tetrahydropalmatine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tetrahydropalmatine.Approved
XenonThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Xenon.Experimental
XipamideTetrahydropalmatine may increase the hypotensive activities of Xipamide.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Tetrahydropalmatine.Vet Approved
XylometazolineXylometazoline may increase the hypotensive activities of Tetrahydropalmatine.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Tetrahydropalmatine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tetrahydropalmatine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Tetrahydropalmatine.Approved
ZofenoprilTetrahydropalmatine may increase the hypotensive activities of Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Tetrahydropalmatine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tetrahydropalmatine.Approved, Investigational
ZolpidemTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tetrahydropalmatine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Tetrahydropalmatine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Tetrahydropalmatine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C02890
ChemSpider
65252
BindingDB
50424077
ChEBI
16563
ChEMBL
CHEMBL487182

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0246 mg/mLALOGPS
logP3.09ALOGPS
logP3.15ChemAxon
logS-4.2ALOGPS
pKa (Strongest Basic)5.34ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.16 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity101.36 m3·mol-1ChemAxon
Polarizability39.97 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as protoberberine alkaloids and derivatives. These are alkaloids with a structure based on a protoberberine moiety, which consists of a 5,6-dihydrodibenzene moiety fused to a quinolizinium and forming 5,6-Dihydrodibenzo(a,g)quinolizinium skeleton.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Protoberberine alkaloids and derivatives
Sub Class
Not Available
Direct Parent
Protoberberine alkaloids and derivatives
Alternative Parents
Tetrahydroisoquinolines / Anisoles / Aralkylamines / Alkyl aryl ethers / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Protoberberine skeleton / Tetrahydroprotoberberine skeleton / Tetrahydroisoquinoline / Anisole / Alkyl aryl ether / Aralkylamine / Benzenoid / Tertiary amine / Tertiary aliphatic amine / Ether
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic heterotetracyclic compound, berberine alkaloid (CHEBI:16563) / Isoquinoline alkaloids (C02890)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Mantsch JR, Li SJ, Risinger R, Awad S, Katz E, Baker DA, Yang Z: Levo-tetrahydropalmatine attenuates cocaine self-administration and cocaine-induced reinstatement in rats. Psychopharmacology (Berl). 2007 Jul;192(4):581-91. Epub 2007 Mar 15. [PubMed:17361394]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Mantsch JR, Li SJ, Risinger R, Awad S, Katz E, Baker DA, Yang Z: Levo-tetrahydropalmatine attenuates cocaine self-administration and cocaine-induced reinstatement in rats. Psychopharmacology (Berl). 2007 Jul;192(4):581-91. Epub 2007 Mar 15. [PubMed:17361394]

Drug created on October 20, 2016 15:20 / Updated on October 02, 2017 06:25